Clinical characteristics and trial drug dosage
| Botulinum toxin group (n=20) | Placebo group (n=20) | |||
|---|---|---|---|---|
| Female sex | 7 (35%) | 10 (50%) | ||
| Age at stroke1-150 | 60.2 (22.6–77.6) | 53.8 (11.2–72.8) | ||
| Time to recruitment (y)1-150 | 3.1 (0.8–33.2) | 2.7 (0.5–15.0) | ||
| Type of stroke - infarct | 15 (75%) | 15 (75%) | ||
| Haemorrhage | 5 (25%) | 5 (25%) | ||
| Right handed | 18 (90%) | 20 (100%) | ||
| Right hemiparesis | 8 (40%) | 6 (30%) | ||
| Barthel index1-150 | 13.5 (4–20) | 13.5 (5–20) | ||
| Botulinum toxin dose(MU) | Patients injected | Saline volume equivalent to dose in MU | Patients injected | |
| Muscles injected:1-150 | ||||
| Biceps brachii | 300 (100–400) | 19 | 300 (150–500) | 19 |
| Brachioradialis | 100 (100–200) | 14 | 100 (100–200) | 12 |
| Flexor digitorum superficialis | 300 (200–500) | 20 | 300 (200–450) | 20 |
| Flexor digitorum profundus | 200 (100–300) | 20 | 200 (100–400) | 20 |
| Flexor carpi ulnaris | 100 (100–200) | 13 | 100 (100–200) | 13 |
↵1-150 Median (range).